The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of gemcitabine, oxaliplatin, and erlotinib (GEMOX-T) combination chemotherapy in previously untreated patients with locally advanced unresectable or metastatic pancreatic cancer.
Jina Yun
No relevant relationships to disclose
Han Jo Kim
No relevant relationships to disclose
Kyoung Ha Kim
No relevant relationships to disclose
Se Hyung Kim
No relevant relationships to disclose
Hyun Jung Kim
No relevant relationships to disclose
Sang-Cheol Lee
No relevant relationships to disclose
Sang Byung Bae
No relevant relationships to disclose
Chan Kyu Kim
No relevant relationships to disclose
Namsu Lee
No relevant relationships to disclose
Kyu Taek Lee
No relevant relationships to disclose
Seong Kyu Park
No relevant relationships to disclose
Jong-Ho Won
No relevant relationships to disclose
Dae Sik Hong
No relevant relationships to disclose
Hee Sook Park
No relevant relationships to disclose
Hyun Jong Choi
No relevant relationships to disclose
Jong Ho Moon
No relevant relationships to disclose